mardi 7 juin 2016

Onco Actu du 7 juin 2016 - spécial ASCO

2.6 Etiologie - Environnement

EU countries refuse to back new license for glyphosate weed-killer [Reuters]

3.1 Tabac

Cigarette-pack warnings work better with photos [Reuters]

5.2 Pharma

Drug makers pay $67m for misleading docs about cancer drug survival data [STAT]

Bristol-Myers Squibb Promises To Publish Failed Study After Long Delay [Forbes]

Christi Shaw: Sad and Inspiring Reason She Stepped Down from Novartis [Fortune]

Big Biotech is here — and it’s starting to look a lot like Big Pharma [STAT]

5.5 ASCO

TAPUR Study Achieves Milestones: Forty-Nine Patients Consent to Participate, Bayer and Merck Sign on as Drug Providers, and Thirty-Seven Sites Are Participating Twelve Weeks Post-Launch [ASCO]

5.5.1 ASCO (général)

Vice President Joe Biden, Speaking at ASCO's 2016 Annual Meeting, Challenges Cancer Community to Expand Data-Sharing to Advance the National Cancer Moonshot [ASCO]

Newly launched Genomic Data Commons to facilitate data and clinical information sharing [NIH]

Biden Designates NCI’s Genomic Data Commons As “Foundational Element” of Cancer Moonshot [The Cancer Letter]

Cancer needs Ebola-level action - Biden [BBC News]

U.S. project launched to promote data sharing by cancer researchers [Reuters] ASCO (général) - Industriels

Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients [Myriad]

Myriad On Genetic Testing For Cancer Risk: Insurance Gap Is A 'Crisis' (Forbes]

Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting [Clovis Oncology]

Cancer Drug Stocks: The Winners and Losers From ASCO 2016 [The Street]

Winners And Losers From Cancer Research's Big Event [Forbes]

5.5.10 ASCO (hémato)

New Phase 3 Secondary Analysis Shows ProgressionFree Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis CarfilzomibBased Regimen [Amgen]

Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1) [Kite]

5.5.12 ASCO (médico-éco)

Cancer drugs, though cheaper in the developing world, remain unaffordable in poorer countries [STAT]

Huge global variation in cost of cancer drugs [Cancer Research UK]

Cancer Drug Retail Prices Vastly Different Between Countries [ASCO]

Cancer drug prices highest in U.S., least affordable in India, China: study [Reuters]

5.5.13 ASCO (divers)

Cancer patients keep getting aggressive end-of-life treatment, despite lack of benefit [STAT]

Many Patients Younger Than 65 Receive Aggressive Care at the End of Life [ASCO]

5.5.15 ASCO (biopsies liquides)

Readers drowning in flawed “liquid biopsy” stories; other coverage throws a lifeline [HealthNewsReview]

5.5.2 ASCO (sein)

Ten years of hormone breast cancer drugs 'may benefit some' [NHS Choices]

Staying on oestrogen-blocking drugs for five extra years 'prevents more breast cancers returning' [Cancer Research UK]

Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery [ASCO]

Breast cancer drug increases survival (BBC News]

5.5.3 ASCO (prostate)

MRI scans help men avoid unnecessary prostate biopsy [Cancer Research UK]

5.5.4 ASCO (immunothérapies)

New Cancer Drugs Fire Up Body’s Hunters in Tumor Hide and Seek [Bloomberg]

Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma [Kite]

Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma [Kite]

5.5.6 ASCO (peau-mélanome)

ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma [Pfizer]

Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma [Novartis]

Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma Continues to Validate Bristol-Myers Squibb’s Immuno-Oncology Combination Approach [BMS]

Novartis study shows skin cancer combo also works on lungs [Reuters]

5.5.8 ASCO (poumon)

Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer [Pfizer]

AbbVie Shares Fall on Low Survival Data for Lung Cancer Drug [Bloomberg]

Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer [Novartis]

ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study [ARIAD]

Mobile-Friendly Web Application Extends Lung Cancer Survival [ASCO]

Ariad Drug Appears To Delay Lung Cancer's Return Longer Than Rival Medicines (Forbes]

5.5.9 ASCO (autres organes)

Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting [Seattle Genetics]

Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer [Merck]

Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting [Exelixis]

6.10 Politiques

Vermont Governor Signs Bill With Possible $10K Fines for Drug Price Hikes [RAPS]

The Future of Cancer Research and the Cancer Drugs Fund [Inside Government]

6.3 Associations

Charity calls for new breast cancer drug to be given to UK women [The Guardian]

6.9 Controverses

The NIH is abandoning vital clinical research centers. That’s a mistake [STAT]

NIH in uproar over report slamming Clinical Center, leadership shakeup [Science]